Compare Abeona Therapeutics Inc (ABEO) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs QUALCOMM, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while QUALCOMM, Inc. trades at $185.54 (market cap $192.85B). The key difference: QUALCOMM, Inc. is far larger — about 516.6× Abeona Therapeutics Inc's market cap, and QUALCOMM, Inc. pays a 2.01% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | QCOM | |
|---|---|---|
Market Cap | $373.32M | $192.85B |
Sector | Health | Technology |
52-Week High | $7.23 | $251.10 |
52-Week Low | $4.17 | $124.07 |
Enterprise Value | $228.22M | $198.32B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Qualcomm (QCOM) trades at $186.48, up 5.8% in the last 24 hours, reflecting strong momentum. The stock exhibits a bearish technical signal but has consistently beaten earnings expectations in recent quarters. Revenue for 2025 reached $44.28 billion, with a net income margin of 22.31%, though this represents a decline from the previous year. The company is actively diversifying into AI, automotive, and data centers, as highlighted at recent industry events like COMPUTEX 2026.
The outlook is mixed; analyst consensus is a 'Buy' with a $221.21 price target, indicating potential upside, but near-term risks include margin pressures and intense competition in the PC and smartphone chip markets. The stock's valuation, with a P/E of 20.05, appears reasonable relative to growth prospects, but investors must weigh the diversification strategy against persistent market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
